Skip to main content
    A

    Azenta Inc (AZTA)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ

    $47.22
    +1.57 (+3.44%)

    Market Cap: $1.91B

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Azenta Inc (AZTA) Earnings: Report Dates and Results

    Updated Nov 10, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Azenta (AZTA) is expected to report earnings on Feb 2, 2027. In the quarter ended Sep 30, 2026, Azenta reported EPS of $0.28, above the $0.11 estimate. It beat the EPS estimate in 5 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    85%(34/40)
    Avg Surprise
    +57.89%
    Streak
    2 Q

    Upcoming Estimates

    Reports Feb 2, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.08
    Range$0.06 - $0.09
    2 analysts
    EPS Revisions
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$0.12-35.7%
    60d ago$0.13-40.0%
    30d ago$0.13-40.0%
    7d ago$0.10-22.4%
    Current$0.08
    Revenue Consensus
    $156.85M
    Range$154.30M - $159.40M
    2 analysts
    Reports May 4, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.10
    Range$0.08 - $0.11
    2 analysts
    EPS Revisions
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$0.13-26.9%
    60d ago$0.14-32.1%
    30d ago$0.14-32.1%
    7d ago$0.11-16.2%
    Current$0.10
    Revenue Consensus
    $156.15M
    Range$151.00M - $161.10M
    4 analysts

    Next Report

    AZTA has an expected report date of Feb 2, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 11.1% below the $0.09 reported for the quarter ended Dec 31, 2025.

    AZTA Earnings Call

    The latest AZTA earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, AZTA beat 34, missed 5 and matched 1. The widest gap in the table came in the quarter ended Jun 30, 2023, when EPS landed 750.00% above the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.28$0.11$0.05 - $0.15+154.55%Beat+33.3%60 up, 2 downNov 10, 2026N/A
    Jun 30, 2026$0.16$0.10$0.08 - $0.15+60.00%Beat-15.8%50 up, 4 downAug 4, 2026$161.18M
    Mar 31, 2026-$0.04$0.14$0.11 - $0.20-128.57%Miss-180.0%50 up, 0 downMay 6, 2026$144.79M
    Dec 31, 2025$0.09$0.13$0.11 - $0.18-30.77%Miss+12.5%70 up, 4 downFeb 4, 2026$148.64M
    Sep 30, 2025$0.21$0.20$0.18 - $0.23+5.00%Beat+16.7%70 up, 1 downNov 21, 2025$158.95M
    Jun 30, 2025$0.19$0.14$0.10 - $0.17+35.71%Beat+18.8%62 up, 3 downAug 5, 2025$143.85M
    Mar 31, 2025$0.05$0.07$0.02 - $0.09-28.57%Miss0.0%60 up, 1 downMay 7, 2025$143.34M
    Dec 31, 2024$0.08$0.06$0.01 - $0.11+33.33%Beat+300.0%60 up, 3 downFeb 5, 2025$147.44M
    Sep 30, 2024$0.18$0.11$0.05 - $0.13+63.64%Beat+38.5%70 up, 0 downNov 12, 2024$151.08M
    Jun 30, 2024$0.16$0.07$0.03 - $0.11+128.57%Beat+23.1%70 up, 0 downAug 6, 2024$144.29M
    Mar 31, 2024$0.05$0.02$0.01 - $0.03+150.00%BeatN/A60 up, 0 downMay 8, 2024$136.35M
    Dec 31, 2023$0.02-$0.03-$0.05 - -$0.01+166.67%Beat-83.3%50 up, 0 downFeb 7, 2024$141.72M
    Sep 30, 2023$0.13$0.02$0.00 - $0.03+550.00%Beat-18.8%61 up, 0 downNov 13, 2023$58.77M
    Jun 30, 2023$0.13-$0.02-$0.07 - $0.02+750.00%Beat+8.3%60 up, 1 downAug 8, 2023$165.95M
    Mar 31, 2023-$0.06-$0.02-$0.06 - $0.02-200.00%Miss-150.0%50 up, 0 downMay 9, 2023$148.40M
    Dec 31, 2022$0.12$0.10$0.01 - $0.12+20.00%Beat0.0%40 up, 0 downFeb 8, 2023$178.37M
    Sep 30, 2022$0.16$0.07$0.04 - $0.12+128.57%Beat-79.5%50 up, 0 downNov 14, 2022$137.57M
    Jun 30, 2022$0.12$0.09$0.08 - $0.12+33.33%Beat-83.3%51 up, 1 downAug 9, 2022$132.74M
    Mar 31, 2022$0.12$0.11$0.10 - $0.12+9.09%Beat-80.3%50 up, 0 downMay 9, 2022$145.54M
    Dec 31, 2021$0.12$0.08$0.06 - $0.09+50.00%Beat-74.5%50 up, 0 downFeb 8, 2022$139.65M
    Sep 30, 2021$0.78$0.77N/A+1.30%Beat+66.0%N/AN/ANov 10, 2021$136.94M
    Jun 30, 2021$0.72$0.69N/A+4.35%Beat+125.0%N/AN/AAug 5, 2021$129.09M
    Mar 31, 2021$0.61$0.51N/A+19.61%Beat+144.0%N/AN/AMay 10, 2021$129.53M
    Dec 31, 2020$0.47$0.42N/A+11.90%Beat+104.3%N/AN/AFeb 2, 2021$118.14M
    Sep 30, 2020$0.47$0.36N/A+30.56%Beat+95.8%N/AN/ANov 10, 2020N/A
    Jun 30, 2020$0.32$0.20N/A+60.00%Beat+60.0%N/AN/AJul 30, 2020$220.35M
    Mar 31, 2020$0.25$0.25N/A0.00%In line+47.1%N/AN/AApr 30, 2020$220.23M
    Dec 31, 2019$0.23$0.24N/A-4.17%Miss+35.3%N/AN/AFeb 6, 2020$210.50M
    Sep 30, 2019$0.24$0.23N/A+4.35%Beat-40.0%N/AN/ANov 6, 2019N/A
    Jun 30, 2019$0.20$0.16N/A+25.00%Beat-56.5%N/AN/AAug 1, 2019$203.88M
    Mar 31, 2019$0.17$0.10N/A+70.00%Beat-57.5%N/AN/AApr 29, 2019$198.39M
    Dec 31, 2018$0.17$0.13N/A+30.77%Beat-46.9%N/AN/AFeb 5, 2019$179.37M
    Sep 30, 2018$0.40$0.38N/A+5.26%Beat+14.3%N/AN/ANov 19, 2018$159.65M
    Jun 30, 2018$0.46$0.43N/A+6.98%Beat+27.8%N/AN/AAug 6, 2018$172.36M
    Mar 31, 2018$0.40$0.36N/A+11.11%Beat+42.9%N/AN/AMay 1, 2018$156.95M
    Dec 31, 2017$0.32$0.29N/A+10.34%Beat+28.0%N/AN/AFeb 1, 2018$142.60M
    Sep 30, 2017$0.35$0.29N/A+20.69%Beat+59.1%N/AN/ANov 9, 2017$16.49M
    Jun 30, 2017$0.36$0.30N/A+20.00%Beat+125.0%N/AN/AAug 2, 2017$181.72M
    Mar 31, 2017$0.28$0.25N/A+12.00%Beat+300.0%N/AN/AApr 27, 2017$169.33M
    Dec 31, 2016$0.25$0.20N/A+25.00%Beat+1150.0%N/AN/AFeb 1, 2017$159.96M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Sep 30, 2026 was $0.49, within 4 cents of the year before. It was $1.24 for the year ended Sep 30, 2017, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Sep 30, 2026$0.49N/A
    Sep 30, 2025$0.53+29.3%
    Sep 30, 2024$0.41+28.1%
    Sep 30, 2023$0.32-38.5%
    Sep 30, 2022$0.52-79.8%
    Sep 30, 2021$2.58+103.1%
    Sep 30, 2020$1.27+62.8%
    Sep 30, 2019$0.78-50.6%
    Sep 30, 2018$1.58+27.4%
    Sep 30, 2017$1.24N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,900 words across 10 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20266,92510
    2026Q2Jun 30, 20268,51810
    2026Q1Mar 31, 20267,80311
    2025Q4Dec 31, 20256,92810
    2025Q3Sep 30, 20255,18911
    2025Q2Jun 30, 20256,7429
    2025Q1Mar 31, 20257,11110
    2024Q4Dec 31, 20247,53810

    2026Q3 Earnings Call

    Opening remarks

    Yvonne Perron Vice President, FP&A and Investor Relations Thank you, operator, and good morning, and welcome to everyone joining us today. We would like to welcome you to our earnings conference call for the third quarter of fiscal year 2026. Our third quarter earnings press release was issued yesterday after market and is available on our Investor Relations website located at investors.azenta.com in addition to the PowerPoint slides and the supplementary information that will be used during the prepared remarks today. Please note that effective the first fiscal quarter of 2025, the results of B Medical Systems are treated as discontinued operations. The previously disclosed sale of the B Medical Systems business was completed on July 1, 2026. I would like to remind everyone that during the course of the call, we will be making a number of forward-looking statements within the meaning of the Private Litigation Securities Act of 1995. There are many factors that may cause actual financial results or other events to differ from those identified in such forward-looking statements. I would refer you to the section of our earnings release titled Safe Harbor Statement, the safe harbor slide on the aforementioned PowerPoint presentation on our website and our various filings with the SEC, including our annual reports on Form 10-K and our quarterly reports on Form 10-Q. We make no obligation to update these statements should future financial data or events occur that differ from the forward-looking statements presented today. We may refer to a number of non-GAAP financial measures, which are used in addition to and in conjunction with results presented in accordance with GAAP. We believe the non-GAAP measures provide an additional way of viewing aspects of our operations and performance, but when considered with GAAP financial results and the reconciliation of GAAP measures, they provide an even more complete understanding of the Azenta business. Non-GAAP measures should not be relied upon to the exclusion of the GAAP measures themselves. On the call with me today is our President and Chief Executive Officer, John Marotta; and our Executive Vice President and Chief Financial Officer, Lawrence Lin. We will begin the call with opening remarks from John, followed by Lawrence, who will provide a detailed review of our financial results and our outlook for fiscal year 2026. We will then take your questions at the end of the prepared remarks. With that, I would like to turn the call over to our CEO, John Marotta.

    John P. Marotta President and Chief Executive Officer Good morning, everyone, and thank you for joining us today. In the third quarter, despite an uneven and challenging market, we made substantial progress delivering against our commitments towards rebuilding confidence through performance. Revenue exceeded our outlook, profitability improved sequentially and Multiomics delivered year-over-year growth.

    Frequently Asked Questions About AZTA

    When is Azenta's next earnings date?

    Azenta's next earnings report is expected for Feb 2, 2027.

    Did AZTA beat earnings estimates last quarter?

    Yes. Azenta reported EPS of $0.28 for the quarter ended Sep 30, 2026, above the $0.11 estimate, a 154.55% surprise.

    What EPS do analysts expect from AZTA next quarter?

    The consensus EPS estimate for Azenta for the quarter ending Dec 31, 2026 is $0.08 from 2 analysts, with estimates from $0.06 to $0.09.

    How often does AZTA beat earnings estimates?

    Azenta beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +12.59%.